AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 35425938 — intervention group
Group type: EXPERIMENTAL
Intervention: Baclofen
Number of subjects: 0
Study 35425938 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35425985 — intervention group
Group type: EXPERIMENTAL
Intervention: Doravirine 100 mg once daily added to stable combined ART for 5 days
Number of subjects: 8
Study 35426046 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegfilgrastim OBI
Number of subjects: 1776
Study 35426046 — intervention group
Group type: COMPARATOR
Intervention: Other options (other G-CSF or none)
Number of subjects: 1776
Study 35426404 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk-score model for lymph node metastases (LN+) based on variables such as age, tumor location, tumor grade, tumor size, and lymphovascular invasion.
Number of subjects: 12228
Study 35426405 — intervention group
Group type: EXPERIMENTAL
Intervention: Biologic, degradable extracellular matrix (ECM)
Number of subjects: 66
Study 35426524 — intervention group
Group type: EXPERIMENTAL
Intervention: Nutritional impact symptoms (NIS)
Number of subjects: 197
Study 35426524 — intervention group
Group type: EXPERIMENTAL
Intervention: Total cumulative NIS
Number of subjects: 197
Study 35426524 — intervention group
Group type: EXPERIMENTAL
Intervention: Factors increasing risk for body weight loss
Number of subjects: 197
Study 35426524 — intervention group
Group type: EXPERIMENTAL
Intervention: Body weight loss
Number of subjects: 197
Study 35426735 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized Soft Tissue Mobilization
Number of subjects: 0
Study 35426861 — intervention group
Group type: EXPERIMENTAL
Intervention: Amoxicillin-clavulanic acid
Number of subjects: 157
Study 35426861 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin-tazobactam
Number of subjects: 157
Study 35426861 — intervention group
Group type: EXPERIMENTAL
Intervention: Meropenem
Number of subjects: 157
Study 35427700 — intervention group
Group type: EXPERIMENTAL
Intervention: MANTA VCD (Teleflex/Essential Medical Inc.)
Number of subjects: 1000
Study 35427703 — intervention group
Group type: EXPERIMENTAL
Intervention: CAVS families with TAV and BAV probands
Number of subjects: 2371
Study 35427703 — intervention group
Group type: COMPARATOR
Intervention: Control families screened for BAV
Number of subjects: 2371
Study 35427833 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab and maraviroc
Number of subjects: 20
Study 35427833 — intervention group
Group type: COMPARATOR
Intervention: Poststudy salvage treatment
Number of subjects: 20
Study 35428207 — intervention group
Group type: EXPERIMENTAL
Intervention: Sn-117 m-DTPA
Number of subjects: 25
Study 35428211 — intervention group
Group type: EXPERIMENTAL
Intervention: IV injection of low activity benzamide-based radioligands targeting melanin
Number of subjects: 0
Study 35428230 — intervention group
Group type: EXPERIMENTAL
Intervention: Malaria self-management kits distributed after training to gold miners.
Number of subjects: 0
Study 35428256 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of rehabilitation processes measured by 11 process indicators (pass rates from 0 to 100%) after 2 months.
Number of subjects: 293
Study 35428256 — intervention group
Group type: EXPERIMENTAL
Intervention: Goal attainment measured by Patient-Specific Functional Scale.
Number of subjects: 293
Study 35428256 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical function measured by 30 s sit-to-stand test.
Number of subjects: 293
Study 35428256 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-related quality of life measured by EuroQoL 5D-5L.
Number of subjects: 293
Study 35428289 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-created multi-component physical activity interventions in nursing care
Number of subjects: 111
Study 35428289 — intervention group
Group type: EXPERIMENTAL
Intervention: Co-created multi-component physical activity interventions in automotive mechatronics
Number of subjects: 111
Study 35428289 — intervention group
Group type: COMPARATOR
Intervention: Co-created multi-component physical activity interventions
Number of subjects: 111
Study 35428342 — intervention group
Group type: EXPERIMENTAL
Intervention: Practice facilitation
Number of subjects: 29
Study 35428342 — intervention group
Group type: COMPARATOR
Intervention: Self-directed control (receipt of TASSH with no practice facilitation)
Number of subjects: 29
Study 35428346 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-tDCS during physical therapy (2 mA for 20 minutes)
Number of subjects: 19
Study 35428346 — intervention group
Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 19
Study 35428346 — intervention group
Group type: EXPERIMENTAL
Intervention: Before stimulation protocol (previous study)
Number of subjects: 19
Study 35428353 — intervention group
Group type: EXPERIMENTAL
Intervention: ICPtcd (Transcranial Doppler)
Number of subjects: 262
Study 35428480 — intervention group
Group type: EXPERIMENTAL
Intervention: Hysteroscopic sterilization
Number of subjects: 29871
Study 35428480 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic sterilization
Number of subjects: 29871
Study 35428649 — intervention group
Group type: EXPERIMENTAL
Intervention: CT imaging for staging
Number of subjects: 0
Study 35428649 — intervention group
Group type: EXPERIMENTAL
Intervention: FDG-PET/CT imaging for staging
Number of subjects: 0
Study 35428657 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous, ex vivo expanded Tregs infusion (1×10^6 cells)
Number of subjects: 1
Study 35428655 — intervention group
Group type: EXPERIMENTAL
Intervention: Thiazolidinedione usage
Number of subjects: 30
Study 35428708 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrolimus
Number of subjects: 170
Study 35428884 — intervention group
Group type: EXPERIMENTAL
Intervention: Lonapegsomatropin
Number of subjects: 0
Study 35428884 — intervention group
Group type: COMPARATOR
Intervention: TransCon hGH Auto-Injector
Number of subjects: 0
Study 35428916 — intervention group
Group type: EXPERIMENTAL
Intervention: GAP score parameters
Number of subjects: 165
Study 35428916 — intervention group
Group type: EXPERIMENTAL
Intervention: Relative lumbar lordosis 15 degrees greater than ideal lumbar lordosis
Number of subjects: 165
Study 35428916 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbar distribution index of 90%
Number of subjects: 165
Study 35428916 — intervention group
Group type: EXPERIMENTAL
Intervention: Age-adjusted offset alignment targets
Number of subjects: 165
Study 35429109 — intervention group
Group type: EXPERIMENTAL
Intervention: FI-35
Number of subjects: 996
Study 35429109 — intervention group
Group type: EXPERIMENTAL
Intervention: FTS-5
Number of subjects: 996
Study 35429109 — intervention group
Group type: EXPERIMENTAL
Intervention: FRAIL scale
Number of subjects: 996
Study 35429115 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating proteins related to adipokine signaling and vascular function (e.g., leptin, vascular endothelial growth factor) in women
Number of subjects: 399
Study 35429115 — intervention group
Group type: EXPERIMENTAL
Intervention: Circulating proteins related to extracellular matrix organization and inflammation (e.g., matrix metalloproteinase-2, C-reactive protein) in men
Number of subjects: 399
Study 35429115 — intervention group
Group type: COMPARATOR
Intervention: Association with cardiovascular outcomes
Number of subjects: 399
Study 35429329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide (4 mg daily), Dexamethasone (20-40 mg weekly), Daratumumab (16 mg/kg)
Number of subjects: 18
Study 35429329 — intervention group
Group type: EXPERIMENTAL
Intervention: Pomalidomide, Dexamethasone, Daratumumab
Number of subjects: 18
Study 35429387 — intervention group
Group type: EXPERIMENTAL
Intervention: Early chronotype
Number of subjects: 34
Study 35429391 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel (175 mg/m2) and Carboplatin (target AUC 6) intravenously every 3 weeks for up to 6 cycles
Number of subjects: 16
Study 35429391 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel and Carboplatin chemotherapy
Number of subjects: 16
Study 35429903 — intervention group
Group type: EXPERIMENTAL
Intervention: Nivolumab
Number of subjects: 0
Study 35429903 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 35430299 — intervention group
Group type: EXPERIMENTAL
Intervention: anti-PD-1 therapy
Number of subjects: 32
Study 35430299 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination immunotherapy for HCC
Number of subjects: 32
Study 35430328 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin
Number of subjects: 0
Study 35430328 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 0
Study 35430710 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision aid for midfacial trauma
Number of subjects: 993
Study 35430710 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical decision aid for mandibular trauma
Number of subjects: 993
Study 35430801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS) to the primary motor cortex of the lesioned hemisphere, combined with standardized rehabilitative training, applied in 10 sessions over 2 weeks.
Number of subjects: 120
Study 35430801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (1:1 randomization)
Number of subjects: 120
Study 35430801 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation (tDCS)
Number of subjects: 120
Study 35431132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine delivery via TAR-200 (two 7-day cycles)
Number of subjects: 23
Study 35431132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine delivery via TAR-200 (Arm 1)
Number of subjects: 23
Study 35431132 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine delivery via TAR-200 (Arm 2)
Number of subjects: 23
Study 35431240 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD individuals (Aβ positive)
Number of subjects: 668
Study 35431240 — intervention group
Group type: EXPERIMENTAL
Intervention: SCD individuals (Aβ negative)
Number of subjects: 668
Study 35431240 — intervention group
Group type: COMPARATOR
Intervention: SCD individuals
Number of subjects: 668
Study 35431355 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsurgical periodontal therapy
Number of subjects: 50
Study 35431559 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive skin prick tests (SPT)
Number of subjects: 11283
Study 35431895 — intervention group
Group type: EXPERIMENTAL
Intervention: Directional deep brain stimulation (dDBS) targeting the fornix, stimulation parameters set between 3.9 and 7.5 mA, 90 μs, 130 Hz for 24 months.
Number of subjects: 1
Study 35431912 — intervention group
Group type: EXPERIMENTAL
Intervention: Psilocybin Assisted Therapy
Number of subjects: 0
Study 35431912 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 35431953 — intervention group
Group type: EXPERIMENTAL
Intervention: ACT-1004-1239
Number of subjects: 0
Study 35432163 — intervention group
Group type: EXPERIMENTAL
Intervention: Prism Adaptation Treatment (PAT)
Number of subjects: 37
Study 35432163 — intervention group
Group type: COMPARATOR
Intervention: Alternative therapies (Control)
Number of subjects: 37
Study 35432170 — intervention group
Group type: EXPERIMENTAL
Intervention: VIP (8 pmol/kg/min)
Number of subjects: 0
Study 35432170 — intervention group
Group type: COMPARATOR
Intervention: Placebo (sterile saline)
Number of subjects: 0
Study 35432194 — intervention group
Group type: EXPERIMENTAL
Intervention: Exenatide treatment
Number of subjects: 35
Study 35432352 — intervention group
Group type: EXPERIMENTAL
Intervention: Anti-CD30 CAR-T therapy combined with PD-1 inhibitor
Number of subjects: 7
Study 35432352 — intervention group
Group type: COMPARATOR
Intervention: Lymphocyte-depleting chemotherapy with fludarabine and cyclophosphamide
Number of subjects: 7
Study 35432994 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic sleeve gastrectomy (SG)
Number of subjects: 49
Study 35433325 — intervention group
Group type: EXPERIMENTAL
Intervention: Western Aphasia Battery-Revised
Number of subjects: 20
Study 35433325 — intervention group
Group type: EXPERIMENTAL
Intervention: Barthel Index
Number of subjects: 20
Study 35433325 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychiatric Inventory
Number of subjects: 20
Study 35433325 — intervention group
Group type: EXPERIMENTAL
Intervention: Domain-specific scales (Stroke Aphasia Depression Questionnaire-10 item version, Starkstein Apathy Scale)
Number of subjects: 20
Study 35433325 — intervention group
Group type: EXPERIMENTAL
Intervention: Adapted version of the Hospital Anxiety and Depression Scale
Number of subjects: 20
Study 35433488 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50 classification (LumA, LumB, HER2E, Basal)
Number of subjects: 1071
Study 35433488 — intervention group
Group type: EXPERIMENTAL
Intervention: PAM50-derived risk of recurrence
Number of subjects: 1071
Study 35433488 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcriptomic pathway analysis
Number of subjects: 1071
Study 35433488 — intervention group
Group type: COMPARATOR
Intervention: Traditional subtypes (HR, HER2, Ki67)
Number of subjects: 1071
Study 35433544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema (with or without a positive skin prick test)
Number of subjects: 0
Study 35433544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema
Number of subjects: 0
Study 35433544 — intervention group
Group type: EXPERIMENTAL
Intervention: Eczema and ADHD
Number of subjects: 0
Study 35433774 — intervention group
Group type: EXPERIMENTAL
Intervention: Probiotic intake (from yoghurts or dietary supplements)
Number of subjects: 888
Study 35433774 — intervention group
Group type: EXPERIMENTAL
Intervention: Ordinary yoghurt intake
Number of subjects: 888
Study 35433774 — intervention group
Group type: COMPARATOR
Intervention: No yoghurt intake
Number of subjects: 888
Study 35433861 — intervention group
Group type: EXPERIMENTAL
Intervention: Jailed Balloon Technique (JBT)
Number of subjects: 284
Study 35433861 — intervention group
Group type: COMPARATOR
Intervention: Jailed Wire Technique (JWT)
Number of subjects: 284
Study 35433879 — intervention group
Group type: EXPERIMENTAL
Intervention: PRIME score (machine learning-based model)
Number of subjects: 220
Study 35433879 — intervention group
Group type: COMPARATOR
Intervention: EuroSCORE II (traditional risk model)
Number of subjects: 220
Study 35433884 — intervention group
Group type: EXPERIMENTAL
Intervention: Chronic Kidney Disease (CKD)
Number of subjects: 2356
Study 35433884 — intervention group
Group type: COMPARATOR
Intervention: Non-Chronic Kidney Disease (non-CKD)
Number of subjects: 2356
Study 35434343 — intervention group
Group type: EXPERIMENTAL
Intervention: Pembrolizumab given 2-3 weeks prior to chemoradiation and then, q21 days concurrently with high-dose cisplatin and radiation prescribed to a total dose of 70 Gy.
Number of subjects: 9
Study 35434451 — intervention group
Group type: EXPERIMENTAL
Intervention: Abaloparatide (ABL) followed by Alendronate (ALN) for 18 months and 24 months respectively
Number of subjects: 0
Study 35434451 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PBO) followed by Alendronate (ALN)
Number of subjects: 0
Study 35434588 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR)
Number of subjects: 17
Study 35434590 — intervention group
Group type: EXPERIMENTAL
Intervention: Metabolomic analysis of serum samples using mass spectrometry
Number of subjects: 627
Study 35434590 — intervention group
Group type: EXPERIMENTAL
Intervention: Analysis of circulating metabolites
Number of subjects: 627
Study 35434590 — intervention group
Group type: EXPERIMENTAL
Intervention: Identification of metabolic transition point
Number of subjects: 627
Study 35434696 — intervention group
Group type: EXPERIMENTAL
Intervention: In-hospital mortality
Number of subjects: 1589
Study 35434696 — intervention group
Group type: EXPERIMENTAL
Intervention: Rehospitalization or death after hospital discharge
Number of subjects: 1589
Study 35434725 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol (100 mg daily, titrated to 800 mg)
Number of subjects: 940
Study 35434725 — intervention group
Group type: COMPARATOR
Intervention: Febuxostat (40 mg daily, titrated to 120 mg)
Number of subjects: 940
Study 35434725 — intervention group
Group type: EXPERIMENTAL
Intervention: Allopurinol and Febuxostat (both treatments)
Number of subjects: 940
Study 35434810 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional dyspepsia symptom diary (FDSD) score
Number of subjects: 512
Study 35434810 — intervention group
Group type: EXPERIMENTAL
Intervention: FDSD ≥ 20
Number of subjects: 512
Study 35434810 — intervention group
Group type: EXPERIMENTAL
Intervention: HAMD ≥ 13
Number of subjects: 512
Study 35434810 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity of FD (mild, moderate, severe)
Number of subjects: 512
Study 35434913 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose pen-injector
Number of subjects: 0
Study 35434913 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidose pen-injector
Number of subjects: 0
Study 35435091 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma Exchange (PE) treatment
Number of subjects: 108
Study 35435111 — intervention group
Group type: EXPERIMENTAL
Intervention: SBRT with 5x7.25 Gy
Number of subjects: 20
Study 35435222 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific antibodies (IgM/IgG) and T-cell responses (CD4+/CD8+)
Number of subjects: 5340
Study 35435222 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific antibodies (IgM/IgG) only
Number of subjects: 5340
Study 35435222 — intervention group
Group type: EXPERIMENTAL
Intervention: T-cell response only
Number of subjects: 5340
Study 35435222 — intervention group
Group type: EXPERIMENTAL
Intervention: Virus-specific antibodies
Number of subjects: 5340
Study 35435625 — intervention group
Group type: EXPERIMENTAL
Intervention: Tarloxotinib 150 mg/m2 on days 1, 8, 15, and 22 in a 28-day cycle
Number of subjects: 30
Study 35435862 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab
Number of subjects: 299
Study 35435862 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab
Number of subjects: 299
Study 35435862 — intervention group
Group type: COMPARATOR
Intervention: Vedolizumab
Number of subjects: 299
Study 35435862 — intervention group
Group type: COMPARATOR
Intervention: Ustekinumab
Number of subjects: 299
Study 35435862 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (for large ileal ulcers)
Number of subjects: 299
Study 35435862 — intervention group
Group type: EXPERIMENTAL
Intervention: Adalimumab (for colonic disease)
Number of subjects: 299
Study 35435862 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (for colonic disease)
Number of subjects: 299
Study 35435984 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous CD7-CAR T-cell infusion
Number of subjects: 8
Study 35436215 — intervention group
Group type: EXPERIMENTAL
Intervention: Interactive digital game combined with traditional rehabilitation (n=12)
Number of subjects: 23
Study 35436215 — intervention group
Group type: COMPARATOR
Intervention: Standard rehabilitation only (n=11)
Number of subjects: 23
Study 35436215 — intervention group
Group type: COMPARATOR
Intervention: Comparison of digital game group vs standard rehabilitation group
Number of subjects: 23
Study 35436215 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction questionnaire for both groups
Number of subjects: 23
Study 35436224 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast immobilization in situ
Number of subjects: 23
Study 35436224 — intervention group
Group type: COMPARATOR
Intervention: Closed reduction with or without percutaneous fixation
Number of subjects: 23
Study 35436224 — intervention group
Group type: EXPERIMENTAL
Intervention: Secondary outcomes
Number of subjects: 23
Study 35436228 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed 4-week mindfulness meditation program
Number of subjects: 80
Study 35436228 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control condition
Number of subjects: 80
Study 35436231 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based psychoeducation (≤16 sessions over 6 months)
Number of subjects: 148
Study 35436231 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 148
Study 35436231 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth-based psychoeducation
Number of subjects: 148
Study 35436231 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate
Number of subjects: 148
Study 35436231 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral antipsychotics
Number of subjects: 148
Study 35436365 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β oestradiol (17βE) starting dose of 12.5 mcg increasing to 25 mcg after 4 months, patch changed twice weekly for a total of 8 months
Number of subjects: 16
Study 35436365 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal 17β oestradiol (17βE)
Number of subjects: 16
Study 35436589 — intervention group
Group type: EXPERIMENTAL
Intervention: LX-039
Number of subjects: 0
Study 35436857 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 100 mg
Number of subjects: 0
Study 35436857 — intervention group
Group type: EXPERIMENTAL
Intervention: Eptinezumab 300 mg
Number of subjects: 0
Study 35436857 — intervention group
Group type: COMPARATOR
Intervention: Eptinezumab 100 mg and 300 mg
Number of subjects: 0
Study 35437054 — intervention group
Group type: EXPERIMENTAL
Intervention: Revascularization
Number of subjects: 20
Study 35437054 — intervention group
Group type: COMPARATOR
Intervention: Exercise ECG stress test (EST)
Number of subjects: 20
Study 35437075 — intervention group
Group type: EXPERIMENTAL
Intervention: POMAQ scoring algorithm
Number of subjects: 112
Study 35437075 — intervention group
Group type: COMPARATOR
Intervention: POMAQ data
Number of subjects: 112
Study 35437075 — intervention group
Group type: EXPERIMENTAL
Intervention: POMAQ and ancillary sources (e.g. electronic medical records, urine toxicity screen)
Number of subjects: 112
Study 35437255 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based training and structured group reflections
Number of subjects: 0
Study 35437257 — intervention group
Group type: EXPERIMENTAL
Intervention: IVUS-guided primary PCI
Number of subjects: 200
Study 35437256 — intervention group
Group type: EXPERIMENTAL
Intervention: BCG immunotherapy
Number of subjects: 0
Study 35437256 — intervention group
Group type: EXPERIMENTAL
Intervention: Microbial community analysis via 16S rDNA gene amplicon sequencing
Number of subjects: 0
Study 35437256 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical prediction model
Number of subjects: 0